Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease.
Alzheimer's disease
Nutritional intervention
Randomized clinical trial
Souvenaid
Synapse activity
Synapse formation
[18F]FDG-PET
Journal
Alzheimer's & dementia (New York, N. Y.)
ISSN: 2352-8737
Titre abrégé: Alzheimers Dement (N Y)
Pays: United States
ID NLM: 101650118
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Alzheimer's disease (AD) is associated with synapse loss. Souvenaid, containing the specific nutrient combination Fortasyn Connect, was designed to improve synapse formation and function. The NL-ENIGMA study explored the effect of Souvenaid on synapse function in early AD by assessing cerebral glucose metabolism (CMRglc) with We conducted an exploratory double-blind randomized controlled single-center trial. Fifty patients with mild cognitive impairment or mild dementia with evidence of amyloid pathology (cerebrospinal fluid or PET) were stratified for MMSE (20-24 and 25-30) and randomly 1:1 allocated to 24-week daily administration of 125 mL Souvenaid (n = 25) or placebo (n = 25). Dynamic 60-minute [ No baseline differences between treatment groups were found (placebo/intervention: n = 25/25; age 66 ± 8/65 ± 7 years; female 44%/48%; MMSE 25 ± 3/25 ± 3). [ In this exploratory trial, we found no robust effect of 24-week intervention with Souvenaid on synapse function measured by [
Identifiants
pubmed: 31650005
doi: 10.1016/j.trci.2019.08.002
pii: S2352-8737(19)30053-8
pmc: PMC6804721
doi:
Types de publication
Journal Article
Langues
eng
Pagination
492-500Subventions
Organisme : HSRD VA
ID : CDP 13-003
Pays : United States
Informations de copyright
© 2019 The Authors.
Références
J Alzheimers Dis. 2018;62(3):1091-1111
pubmed: 29562540
Neurobiol Aging. 2014 Mar;35(3):576-84
pubmed: 24269021
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Neuroimage. 2002 Sep;17(1):302-16
pubmed: 12482085
Hum Brain Mapp. 2002 Mar;15(3):165-74
pubmed: 11835607
J Alzheimers Dis. 2012;31(1):225-36
pubmed: 22766770
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90
pubmed: 4055928
Hum Brain Mapp. 2014 Jan;35(1):297-308
pubmed: 22965806
Eur J Pharmacol. 2011 Sep;668 Suppl 1:S59-69
pubmed: 21816137
Alzheimers Res Ther. 2017 Jul 26;9(1):51
pubmed: 28747210
Alzheimers Dement (N Y). 2016 Sep 01;2(4):233-240
pubmed: 29067310
PLoS One. 2014 Jan 27;9(1):e86558
pubmed: 24475144
Lancet Neurol. 2017 Dec;16(12):965-975
pubmed: 29097166
Neurobiol Dis. 2014 Dec;72 Pt A:117-22
pubmed: 24825318
Ned Tijdschr Psychol. 1964 May-Jun;19:247-54
pubmed: 14168788
Alzheimers Dement. 2014 Nov;10(6):713-723.e2
pubmed: 24721526
Neurobiol Aging. 2011 Jul;32(7):1207-18
pubmed: 19660834
Am J Geriatr Psychiatry. 2014 Oct;22(10):961-70
pubmed: 24495404
Annu Rev Nutr. 2009;29:59-87
pubmed: 19400698
J Neurol. 1995 Sep;242(9):557-60
pubmed: 8551316
Alzheimers Dement. 2010 Jan;6(1):1-10.e1
pubmed: 20129316
J Alzheimers Dis. 2014;38(3):459-79
pubmed: 23985420
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9
pubmed: 14688411
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Nutrition. 2013 Sep;29(9):1080-9
pubmed: 23756280